THINK Surgical gained FDA 510(k) clearance for use of b-ONE Ortho’s MOBIO with TMINI in 2024.
Nanochon Chondrograft will be evaluated in a first in human study for use in knee cartilage restoration in eligible patients.
The trial will compare safety and effectiveness of Triadyme-C to ACDF in the treatment of symptomatic cervical disc disease.
THINK Surgical gained FDA 510(k) clearance for use of b-ONE Ortho’s MOBIO with TMINI in 2024.
Nanochon Chondrograft will be evaluated in a first in human study for use in knee cartilage restoration in eligible patients.
The trial will compare safety and effectiveness of Triadyme-C to ACDF in the treatment of symptomatic cervical disc disease.
The system supports treatment of scapular fractures using several different techniques, including single and dual plating.
VISIE’s scanning platform is completely non-invasive and employs no bone-pinned trackers, clamps or registration steps.
The novel device is designed to provide a minimally invasive option for patients suffering from facet joint-related pain or instability.
Highridge licensed U.S. rights to activL and is commencing production for the launch of its own activL lumbar disc later this year.
Of the more than 350 spinal bone grafts in the U.S. market, Cerapedics has two of only three spinal bone grafts that have successfully gone through the PMA process.
Oxiplex is an intraoperative gel indicated as an adjunct to lumbar spinal surgery to reduce post-op leg pain and neurological symptoms.
The BEAR MOON study will compare the BEAR Implant to autograft bone-patellar tendon-bone anterior cruciate ligament reconstruction.
Made from BIOLOX delta ceramic, ReCerf eliminates concerns associated with metal-on-metal bearings and preserves more of the patient’s natural bone.
CORE is designed to assist in the placement of the K-wire for the glenoid component during total shoulder replacement.
The third-generation cervical spine cage utilizes BGS-7, a new bioactive glass-ceramic material, that may be more biocompatible than titanium or PEEK cages.
Results show a fusion rate of 88.4% in a highly complex patient cohort, demonstrating that Catalyst nanosynthetic bone graft shows strong performance even in challenging patient populations.
Incompass incorporates Adaptis Boney Ingrowth Technology and redesigned instrumentation to support long-term fixation, surgical flexibility and streamlined workflow.
Login
Register for a free account
As a guest member you get access to more articles and videos every month.